T helper 17 cells and B cells can work in concert to spark long-lasting protection against solid tumors, a research team at Winship Cancer Institute of Emory University found.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.
Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.
Van Andel Institute scientists have developed an improved technique to comprehensively profile DNA methylation in single cells, an advance that will help researchers better study the role of epigenetics in cancer and other diseases.
Researchers develop nicotinamide N-methyl transferase inhibitor to block ovarian cancer tumor growth
A team led by researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase, an enzyme that is involved in the progression of high-grade serous ovarian cancer.
A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.
Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body’s natural defenses.
NCI has initiated a pilot study to address the feasibility of using multi-cancer detection, or MCD, tests in future randomized controlled trials.
The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.
